Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ono Pharmaceutical CoOPHLF 73 3-Year EBITDA Growth Rate is -4.90% as of Jun. 2026. GuruFocus rates OPHLF with a GF Score™ of 73/100 and a GF Value™ of $12.17 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 805 Drug Manufacturers companies, Ono Pharmaceutical Co ranks worse than 74.66% on this metric.
During the past 12 months, Ono Pharmaceutical Co's average EBITDA Per Share Growth Rate was 64.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -4.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 1.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ono Pharmaceutical Co was 45.10% per year. The lowest was -17.10% per year. And the median was 1.00% per year.
Ono Pharmaceutical Co (OTCPK:OPHLF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ono Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms
OPHLF vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.
Ono Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -4.90% mean?
Ono Pharmaceutical Co (OPHLF) has a 3-Year EBITDA Growth Rate of -4.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ono Pharmaceutical Co and its competitors. According to the industry distribution chart, Ono Pharmaceutical Co ranks #601 out of 805 companies in the Drug Manufacturers industry, placing it in the top 74.7%.
Is Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate too high?
Ono Pharmaceutical Co's current 3-Year EBITDA Growth Rate is -4.90%. Based on the distribution chart, Ono Pharmaceutical Co ranks #601 out of 805 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ono Pharmaceutical Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #601 out of 805 companies for 3-Year EBITDA Growth Rate. This places Ono Pharmaceutical Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ono Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ono Pharmaceutical Co's current 3-Year EBITDA Growth Rate is -4.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (OPHLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.17, compared to a current price of $15.00 — trading 23.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -4.90%. Ono Pharmaceutical Co's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ono Pharmaceutical Co (OPHLF), the current 3-Year EBITDA Growth Rate is -4.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (OPHLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of $15.00 is trading 23.3% above its estimated GF Value™ of $12.17.
GuruFocus considers Ono Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for OPHLF:
3-Year EBITDA Growth Rate: -4.90%
GF Value™: $12.17 vs. price of $15.00 (23.3% above fair value)
No single metric tells the full story. See the OPHLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
73GF Score
Get the complete analysis for OPHLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPHLF has been successfully added to your 
